Aortic Endograft Market Growth Analysis Till 2033 By The Business Research Company
The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.
Strong Historical Growth
- Market Size: Grew from $3.14 billion in 2023 to $3.35 billion in 2024.
- CAGR: 6.7%.
- Key Drivers:
- Growth in medical tourism.
- Increasing need for aortic aneurysm management.
- Rising number of aortic aneurysm cases.
- Technical success of endograft implantation.
- Increase in the number of hospitals.
Promising Future Outlook
- Expected Growth: Projected to reach $4.08 billion by 2028.
- CAGR: 5.1%.
- Key Drivers:
- Increasing prevalence of abdominal aortic aneurysm.
- Growing preference for minimally invasive procedures.
- Rising geriatric population.
- Advancements in stent-graft materials and configurations.
- Introduction of new stent-graft products.
Read More On The Aortic Endograft Market Report 2024 – https://www.thebusinessresearchcompany.com/report/aortic-endograft-global-market-report
Market Trends and Innovations
- Trends:
- Adoption of endovascular abdominal aortic aneurysm (AAA) repair devices.
- Effectiveness of unibody and non-unibody aortic stents.
- Product innovation.
Rising Incidence of Aortic Aneurysms
- Aortic Aneurysms: Localized dilation or bulging of the aorta.
- Treatment: Aortic endografts are less invasive than traditional surgery, involving a fabric-covered metal or polymer device inserted via a catheter.
- Screening Statistics: In the UK, 274,800 men were screened between April 2021 and March 2022, identifying 1,794 aneurysms.
Key Players in the Market
- Major Companies:
- Cardinal Health Inc.
- Abbott Laboratories
- Medtronic Plc
- Becton, Dickinson and Company
- Koninklijke Philips N.V.
- Boston Scientific Corporation
- Terumo Corporation
- W. L. Gore & Associates Inc.
- Cook Medical Inc.
- Merit Medical Systems Inc.
- Penumbra Inc.
- LifeTech Scientific Corporation
- Altura Medical Inc.
- MicroVention Inc.
- MicroPort Scientific Corporation
- CryoLife Inc.
- Cordis Corporation
- Endologix LLC
Innovations in Medical Devices
- Castor-Branched Aortic Stent Graft System:
- Manufacturer: Shanghai MicroPort Endovascular MedTech Group Co. Ltd.
- Launch: December 2021.
- Features: Minimally invasive repair of aorta and aortic arch, especially in Stanford type B aortic dissection (TBAD). Unique unibody design conforming to diverse arch anatomies, offering one-time access and release, and promoting long-term stability.
Strategic Acquisitions
- Endologix LLC: Acquired PQ Bypass Inc. in April 2021.
- Objective: Expand and reinforce its position in abdominal aortic aneurysm treatment.
- PQ Bypass Inc.: US-based medical device company specializing in aortic endografts.
Market Segmentation
- By Product:
- Abdominal Aortic Grafts.
- Thoracic Aortic Grafts.
- By Material:
- Metallic Endografts.
- Polymeric Endografts.
- By Procedure:
- Open Surgical Repair.
- Endovascular Aneurysm Repair (EVAR).
- By End User:
- Hospitals.
- Ambulatory Surgical Centers.
Regional Insights
- Largest Region (2023): North America.
- Fastest-Growing Region (Forecast Period): Asia-Pacific.
Request for A Sample Of The Global Aortic Endograft Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=13784&type=smp